AIA Group Ltd grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,641 shares of the biopharmaceutical company's stock after buying an additional 621 shares during the quarter. AIA Group Ltd's holdings in Regeneron Pharmaceuticals were worth $11,186,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently bought and sold shares of REGN. SteelPeak Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock valued at $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company's stock valued at $8,317,000 after purchasing an additional 941 shares during the last quarter. Tri Locum Partners LP lifted its position in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock worth $18,410,000 after buying an additional 8,949 shares in the last quarter. Tidal Investments LLC lifted its position in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock valued at $4,774,000 after purchasing an additional 711 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $1,232,000. 83.31% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a report on Friday, November 1st. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Tuesday, July 23rd. Finally, Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $1,092.62.
Check Out Our Latest Stock Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Trading Up 0.5 %
Regeneron Pharmaceuticals stock traded up $3.93 during trading on Friday, hitting $828.41. The company's stock had a trading volume of 340,871 shares, compared to its average volume of 521,284. The stock's fifty day moving average is $1,035.92 and its 200 day moving average is $1,038.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1-year low of $783.57 and a 1-year high of $1,211.20. The stock has a market capitalization of $91.03 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 3.12 and a beta of 0.15.
Insider Buying and Selling
In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.48% of the stock is currently owned by company insiders.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
